{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:48:38Z","timestamp":1793191718576,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtha.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T07:33:37Z","timestamp":1680939217000},"page":"1493-1502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["In\u00a0vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays"],"prefix":"10.1016","volume":"21","author":[{"given":"Jacob","family":"Lund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Ezban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.03.007_bib1","first-page":"141","article-title":"Extended half-life coagulation factors: a new era in the management of hemophilia patients","volume":"36","author":"Ar","year":"2019","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.jtha.2023.03.007_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/2040620718796429","article-title":"Practical aspects of extended half-life products for the treatment of haemophilia","volume":"9","author":"Lambert","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2023.03.007_bib3","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.03.007_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.007_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A\u00a0factor VIIIa\u2013mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.007_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A\u00a0hemophilia A mouse model for the in\u00a0vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.007_bib9","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A\u00a0novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib10","article-title":"FRONTIER1: a phase 1\/2 dose escalation study of a novel factor VIIIa mimetic bispecific antibody, Mim8, for evaluation of safety, pharmacokinetics, and efficacy","author":"Chowdary","year":"2022","journal-title":"ISTH"},{"key":"10.1016\/j.jtha.2023.03.007_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14712598.2019.1626370","article-title":"Emicizumab for the prevention of bleeds in hemophilia A","volume":"19","author":"Mahlangu","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtha.2023.03.007_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In\u00a0vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib13","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"Ninivaggi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2023.03.007_bib17","first-page":"477","article-title":"In\u00a0vitro characterization of an activated prothrombin concentrate and the effects of individual components in combination with rFVIIa","volume":"24","author":"Blouse","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.007_bib18","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib19","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/hae.14024","article-title":"Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia","volume":"27","author":"Parunov","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(03)00025-0","article-title":"Activation of factor VIII and mechanisms of cofactor action","volume":"18","author":"Fay","year":"2004","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2023.03.007_bib22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.03.007_bib23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jth.12197","article-title":"Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness","volume":"11","author":"Yada","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.14430","article-title":"Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence","volume":"17","author":"Leksa","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MBC.0000000000000921","article-title":"A\u00a0bispecific antibody demonstrates limited measurability in routine coagulation assays","volume":"31","author":"Hartmann","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.03.007_bib26","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1074\/jbc.M707234200","article-title":"Characterization of novel forms of coagulation factor XIa: independence of factor XIa subunits in factor IX activation","volume":"283","author":"Smith","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.03.007_bib27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2010.03899.x","article-title":"Coagulation procofactor activation by factor XIa","volume":"8","author":"Whelihan","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/jth.15087","article-title":"A\u00a0serine loop in tissue factor mediates substrate selectivity by the tissue factor\u2013factor VIIa complex","volume":"19","author":"Birkle","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia\u2013an in\u00a0vitro study","volume":"5","author":"Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.007_bib30","article-title":"PO004 Assessing factor VIII activity in the presence of Mim8 via chromogenic assays. 15th Annual Congress of European Association for Haemophilia and Allied Disorders","author":"Pickering","year":"2022","journal-title":"Virtual Meeting"},{"key":"10.1016\/j.jtha.2023.03.007_bib31","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1055\/s-0040-1710032","article-title":"Synergistic effect of bypassing agents and sequence identical analogue of emicizumab and fibrin clot structure in the in\u00a0vitro model of hemophilia A","volume":"4","author":"Zong","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2023.03.007_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.007_bib33","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2023.03.007_bib34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1055\/s-0040-1714279","article-title":"Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A","volume":"120","author":"Gelbenegger","year":"2020","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:53Z","timestamp":1761536333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1538783623002349"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.007","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}